Global Blood Therapeutics' Voxelotor On Track For 2020 Sickle Cell Shakeup

The company's NDA for voxelotor was accepted by the US FDA for priority review with action expected in February, setting up a showdown with Novartis.

Racecar-finishline
GBT's voxelotor races towards the market • Source: Shutterstock

Global Blood Therapeutics Inc. will be poised to launch voxelotor, a new treatment for sickle cell disease, in early 2020 if its US Food and Drug Administration review goes smoothly, setting up a tight race with Novartis AG to bring new treatments to market for sickle cell disease, an area of high unmet medical need with limited treatment options.

GBT's new drug application (NDA) for voxelotor was accepted by the FDA with a priority review and a target action...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Blood and Clotting

More from Therapeutic Category